STOCK TITAN

[144] ANI Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

ANI Pharmaceuticals, Inc. (ANIP) Form 144 reports a proposed sale of 6,865 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $616,223.68. The filing lists the approximate number of shares outstanding as 21,688,772 and an approximate sale date of 08/18/2025 on NASDAQ.

The shares were acquired on 05/23/2024 as restricted stock from the issuer, with payment recorded on the same date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that they do not possess undisclosed material adverse information.

ANI Pharmaceuticals, Inc. (ANIP) — Modulo 144 segnala la proposta di vendita di 6.865 azioni ordinarie tramite Morgan Stanley Smith Barney LLC, per un valore complessivo di mercato di $616,223.68. La comunicazione indica un numero approssimativo di azioni in circolazione pari a 21,688,772 e una data di vendita prevista per il 18/08/2025 sul NASDAQ.

Le azioni erano state acquisite in data 23/05/2024 come restricted stock dall'emittente, con pagamento registrato nello stesso giorno. Il dichiarante segnala di non aver effettuato vendite di titoli dell'emittente negli ultimi tre mesi e include la dichiarazione standard di non essere in possesso di informazioni materiali negative non divulgate.

ANI Pharmaceuticals, Inc. (ANIP) — Formulario 144 informa sobre una propuesta de venta de 6,865 acciones ordinarias a través de Morgan Stanley Smith Barney LLC, con un valor de mercado agregado de $616,223.68. La presentación indica un número aproximado de acciones en circulación de 21,688,772 y una fecha de venta prevista para el 18/08/2025 en NASDAQ.

Las acciones se adquirieron el 23/05/2024 como restricted stock del emisor, con el pago registrado ese mismo día. El declarante informa no haber vendido valores del emisor en los últimos tres meses e incluye la representación estándar de no poseer información adversa material no divulgada.

ANI Pharmaceuticals, Inc. (ANIP) — Form 144는 Morgan Stanley Smith Barney LLC를 통해 보통주 6,865주를 총 시가 $616,223.68에 매도할 예정이라고 보고합니다. 보고서에는 대략적인 발행 주식 수를 21,688,772주로 기재하고 있으며, NASDAQ에서의 예정 매도일은 2025/08/18로 명시되어 있습니다.

해당 주식은 2024/05/23에 발행사로부터 restricted stock으로 취득했으며, 같은 날 결제가 이루어졌습니다. 제출인은 지난 3개월 동안 발행사의 증권을 매도한 적이 없음을 보고하며, 공개되지 않은 중요한 악재성 정보는 보유하고 있지 않다는 표준 진술을 포함하고 있습니다.

ANI Pharmaceuticals, Inc. (ANIP) — Formulaire 144 signale une proposition de vente de 6,865 actions ordinaires via Morgan Stanley Smith Barney LLC, pour une valeur marchande totale de $616,223.68. Le dépôt indique un nombre approximatif d'actions en circulation de 21,688,772 et une date de vente prévue au 18/08/2025 sur le NASDAQ.

Les actions ont été acquises le 23/05/2024 en tant que restricted stock auprès de l'émetteur, le paiement ayant été enregistré le même jour. Le déposant déclare n'avoir réalisé aucune vente de titres de l'émetteur au cours des trois derniers mois et inclut la déclaration standard selon laquelle il ne détient pas d'informations défavorables importantes non divulguées.

ANI Pharmaceuticals, Inc. (ANIP) — Formular 144 meldet einen geplanten Verkauf von 6.865 Stammaktien über Morgan Stanley Smith Barney LLC mit einem Gesamtmarktwert von $616,223.68. Die Einreichung nennt die ungefähre Anzahl der ausstehenden Aktien mit 21,688,772 und ein voraussichtliches Verkaufsdatum am 18.08.2025 an der NASDAQ.

Die Aktien wurden am 23.05.2024 als restricted stock vom Emittenten erworben, die Zahlung wurde am selben Tag verbucht. Der Meldende gibt an, in den letzten drei Monaten keine Wertpapiere des Emittenten verkauft zu haben, und fügt die übliche Erklärung hinzu, keine unveröffentlichten wesentlichen negativen Informationen zu besitzen.

Positive
  • Notice filed under Rule 144 with broker identified (Morgan Stanley Smith Barney LLC)
  • Full acquisition details provided: date, nature (restricted stock), and source (issuer)
  • No sales in the past three months reported, clarifying recent trading activity
Negative
  • None.

Insights

TL;DR: Routine Rule 144 notice for a proposed sale of restricted shares; disclosure aligns with regulatory requirements.

The filing documents a proposed sale under Rule 144 using a registered broker, naming Morgan Stanley Smith Barney LLC, and provides required details: class, quantity, acquisition date, nature of acquisition, aggregate market value, and intended sale date. The inclusion of a statement that there have been no sales in the past three months and the standard attestation about material non-public information are consistent with standard compliance practices for insiders or restricted holders preparing to sell.

TL;DR: Small, disclosed sale of restricted shares; unlikely to be materially impactful to ANIP’s capitalization.

The notice specifies 6,865 shares valued at $616,223.68 and lists 21,688,772 shares outstanding, with the shares acquired from the issuer as restricted stock on 05/23/2024. The filing contains no indication of prior recent sales and does not report any unusual transaction structures. From an investor-information standpoint, this is a transparent disclosure of a planned sale rather than a material corporate event.

ANI Pharmaceuticals, Inc. (ANIP) — Modulo 144 segnala la proposta di vendita di 6.865 azioni ordinarie tramite Morgan Stanley Smith Barney LLC, per un valore complessivo di mercato di $616,223.68. La comunicazione indica un numero approssimativo di azioni in circolazione pari a 21,688,772 e una data di vendita prevista per il 18/08/2025 sul NASDAQ.

Le azioni erano state acquisite in data 23/05/2024 come restricted stock dall'emittente, con pagamento registrato nello stesso giorno. Il dichiarante segnala di non aver effettuato vendite di titoli dell'emittente negli ultimi tre mesi e include la dichiarazione standard di non essere in possesso di informazioni materiali negative non divulgate.

ANI Pharmaceuticals, Inc. (ANIP) — Formulario 144 informa sobre una propuesta de venta de 6,865 acciones ordinarias a través de Morgan Stanley Smith Barney LLC, con un valor de mercado agregado de $616,223.68. La presentación indica un número aproximado de acciones en circulación de 21,688,772 y una fecha de venta prevista para el 18/08/2025 en NASDAQ.

Las acciones se adquirieron el 23/05/2024 como restricted stock del emisor, con el pago registrado ese mismo día. El declarante informa no haber vendido valores del emisor en los últimos tres meses e incluye la representación estándar de no poseer información adversa material no divulgada.

ANI Pharmaceuticals, Inc. (ANIP) — Form 144는 Morgan Stanley Smith Barney LLC를 통해 보통주 6,865주를 총 시가 $616,223.68에 매도할 예정이라고 보고합니다. 보고서에는 대략적인 발행 주식 수를 21,688,772주로 기재하고 있으며, NASDAQ에서의 예정 매도일은 2025/08/18로 명시되어 있습니다.

해당 주식은 2024/05/23에 발행사로부터 restricted stock으로 취득했으며, 같은 날 결제가 이루어졌습니다. 제출인은 지난 3개월 동안 발행사의 증권을 매도한 적이 없음을 보고하며, 공개되지 않은 중요한 악재성 정보는 보유하고 있지 않다는 표준 진술을 포함하고 있습니다.

ANI Pharmaceuticals, Inc. (ANIP) — Formulaire 144 signale une proposition de vente de 6,865 actions ordinaires via Morgan Stanley Smith Barney LLC, pour une valeur marchande totale de $616,223.68. Le dépôt indique un nombre approximatif d'actions en circulation de 21,688,772 et une date de vente prévue au 18/08/2025 sur le NASDAQ.

Les actions ont été acquises le 23/05/2024 en tant que restricted stock auprès de l'émetteur, le paiement ayant été enregistré le même jour. Le déposant déclare n'avoir réalisé aucune vente de titres de l'émetteur au cours des trois derniers mois et inclut la déclaration standard selon laquelle il ne détient pas d'informations défavorables importantes non divulguées.

ANI Pharmaceuticals, Inc. (ANIP) — Formular 144 meldet einen geplanten Verkauf von 6.865 Stammaktien über Morgan Stanley Smith Barney LLC mit einem Gesamtmarktwert von $616,223.68. Die Einreichung nennt die ungefähre Anzahl der ausstehenden Aktien mit 21,688,772 und ein voraussichtliches Verkaufsdatum am 18.08.2025 an der NASDAQ.

Die Aktien wurden am 23.05.2024 als restricted stock vom Emittenten erworben, die Zahlung wurde am selben Tag verbucht. Der Meldende gibt an, in den letzten drei Monaten keine Wertpapiere des Emittenten verkauft zu haben, und fügt die übliche Erklärung hinzu, keine unveröffentlichten wesentlichen negativen Informationen zu besitzen.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the ANIP Form 144 report?

The filing reports a proposed sale of 6,865 common shares with an aggregate market value of $616,223.68, to be sold through Morgan Stanley Smith Barney LLC on or about 08/18/2025.

When and how were the shares acquired for this ANIP Form 144?

The shares were acquired on 05/23/2024 as restricted stock from the issuer, with payment recorded on the same date.

Does the filing indicate recent sales of ANIP shares by the filer?

The filing states Nothing to Report for securities sold during the past three months, indicating no reported recent sales.

Which exchange and broker are involved in the proposed ANIP sale?

The proposed sale is listed for NASDAQ and the broker named is Morgan Stanley Smith Barney LLC.

What statement does the filer make about material non-public information?

The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.
Ani Pharmaceutic

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Latest SEC Filings

ANIP Stock Data

1.90B
18.06M
11.08%
101%
9.82%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
BAUDETTE